By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Pharmigene today said it has licensed its intellectual property to the Mayo Clinic to develop tests to detect the presence of genetic alleles that may put patients who receive certain drugs at greater risk for developing Stevens-Johnson Syndrome and toxic epidermal necrolysis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.